New Product LAB|HiXpan® NK Serum-Free Culture Kit (Cytokine-Based) for Stimulating CBNK Cell Cultures
Release Date:
2025-04-24 15:11
HiXpan Registered trademark NK Cell Serum-Free Culture Kit (Cytokine-Based) Validation data for CBNK stimulated culture in the 2L system
Stimulate the culture of CBNK
Time: 20250304–20250326
Sample 1: Cryopreserved CBMC, Batch No. CBMC DONOR1-20231108
Cell inoculation quantity: 21 million (3 × 10^6 cells/mL, 7 mL)
Initial NK cell purity: CD3−CD56+ proportion approximately 11.4%
01
Stimulus culture results
D0: 21 million CBMCs were seeded and cultured with stimulation for 20 days:
Approximately 8.85 billion umbilical cord blood NK cells were harvested;
Total cell expansion of approximately 421-fold;
The NK cell viability was 93.6%;
NK cell purity: CD3−CD56+ proportion approximately 95.0%, CD56+CD16+ proportion approximately 88.7%.
02
Flow cytometry result plot
Stimulate the culture of CBNK
Time: 20250304–20250326
Sample 2: Cryopreserved CBMC, Batch No. CBMC-20240312
Cell inoculum: 24 million (3 × 10^6 cells/mL, 8 mL)
Initial NK cell purity: CD3−CD56+ proportion approximately 10.3%.
01
Stimulus culture results
D0: 24 million CBMCs were seeded and cultured with stimulation for 20 days:
Approximately 12.3 billion umbilical cord blood NK cells were harvested;
Total cell expansion of approximately 512-fold;
The NK cell viability was 97.1%.
NK cell purity: CD3−CD56+ proportion approximately 84.7%, and CD56+CD16+ proportion approximately 84.1%.
02
Flow cytometry result plot
Stimulate the culture of CBNK
Date: 20250209–20250302
Sample 3: Cryopreserved CBMC, Batch No. JCBMC-20231016
Cell inoculum: 27.8 million (3 × 10^6 cells/mL, 9.27 mL)
Initial NK cell purity: CD3−CD56+ proportion approximately 11.7%
01
Stimulus culture results
D0: 27.8 million CBMCs were seeded and cultured with stimulation for 21 days:
Approximately 31.8 billion umbilical cord blood NK cells were harvested;
Total cell expansion of approximately 1,145-fold;
NK cell viability was 96.6%;
NK cell purity: CD3−CD56+ proportion approximately 98.3%, CD56+CD16+ proportion approximately 92.2%.
02
Flow cytometry result plot
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board